Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Information for patients and caregivers on how to manage adverse events from immune checkpoint inhibitors
New NCCN guidelines explain how to recognize and manage immunotherapy-related toxicities.
Sociodemographic factors may play a role in whether people receive immunotherapy.
The 2020 MRA Scientific Retreat provides updates on the latest melanoma research.
Similar to CAR-T cells, CAR-NK cells are reprogrammed with artificial receptors to recognize and attack cancer.
Checkpoint inhibitor extended survival by about three months compared with chemotherapy.
“Potentially practice-changing” data show patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo.
June is Cancer Immunotherapy Month
Damon Runyon-Rachleff Innovator Rushika M. Perera, PhD, and colleagues may have found an answer.
Initial treatment with atezolizumab led to longer overall survival in people with high biomarker levels.
The combination led to improved overall survival compared with chemotherapy.
The immune-modulating drug was approved to treat the rare cancer in HIV-positive and HIV-negative people.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.